Navigation Links
Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
Date:3/25/2009

CARLSBAD, Calif., March 25 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Citi's 4th Annual Biotech Day on Wednesday, April 1, 2009, at 2:00 p.m. ET at the 388 Greenwich Street Conference Center in New York, NY.

A live audio webcast of the presentation will be available on the "Investor Center" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
2. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
3. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
4. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
5. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
6. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
7. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
9. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
11. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... TORONTO , Sept. 11, 2014 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), announces that it intends ... to US$ 2 million for funding its preclinical ... Holding Company Limited, ("Biohaven"). The Company ... up to 20 million common shares at a ...
(Date:9/11/2014)... Awarded annually by Germany’s Design Zentrum ... recognized quality label for excellent design. METTLER TOLEDO ... Red Dot award in recognition of ... Dispenser (HPD). , The Quantos Handheld Powder ... ease-of-use to applications involving free-flowing powders. Forget the ...
(Date:9/11/2014)... Calif. and LONDON ... and Cancer Research Technology (CRT), the charity,s development ... Inc. (OTCBB: ASTY), a biotechnology company in the ... Asterias, novel immunotherapy treatment AST-VAC2 into clinical trials ... AST-VAC2 represents the tenth treatment to enter ...
(Date:9/10/2014)... 2014 Rutgers University’s Center for ... Dermatological Sciences conference Oct. 8 in New Brunswick. ... university, industry and government sectors can collaborate to ... This conference is unique in bringing together experts ... share their successes, best-practices, and lessons learned. Among ...
Breaking Biology Technology:Portage Announces Proposed Private Placement 2Portage Announces Proposed Private Placement 3Portage Announces Proposed Private Placement 4METTLER TOLEDO Handheld Powder Receives Red Dot Award for Product Design 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 4Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 5Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 6Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 7Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 8Innovations in Dermatological Sciences 2014 2Innovations in Dermatological Sciences 2014 3
... biomass and enzymes to produce hydrogen fuel, ethanol, and ... AgVest in Lake Delton last Thursday. , ,These ... the conference by the AgVest group, which focuses on ... specific recommendations, AgVest tries to hook up up-and-coming agricultural ...
... a PeopleSoft database for tracking alumni in favor ... used for 12 years. , ,Schools and colleges can access ... based on a database from 4D, Inc. , ... separate from the university. When the central database failed to ...
... has been less than overwhelming to Governor Jim Doyles ... private money in Wisconsins biotechnology future. Budget-conscious members of ... of stem-cell research have once again protested, and Milwaukee ... of Madison. , ,Doyle should address all legitimate gripes ...
Cached Biology Technology:Investors hear about new agricultural technology 2Alumni Association extends database help to university 2Alumni Association extends database help to university 3Wisconsin cannot afford to take a pass on Doyles biotech plan 2Wisconsin cannot afford to take a pass on Doyles biotech plan 3
(Date:9/11/2014)... treatise "Flora of Northumberland and Durham" by Nathaniel ... Books platform as an example of combining modern ... new sort of resource and data re-use. This publication ... the region, which can be seen as a model ... enriched re-publication marries the meticulous detail of old ...
(Date:9/11/2014)... Northeastern University researchers and their international colleagues have ... role of neutral evolution in the biogeographic distribution ... Thursday in the journal Science . The ... a neutral agent-based model"was co-authored by Ferdi Hellweger, ... of civil and environmental engineering; his doctoral student ...
(Date:9/11/2014)... -- Today at the TEDMED conference, Tute Genomics announced ... genome sequencing results at the fingertips of the individual ... The $1000 was announced earlier this year by Illumina, ... point towards widespread adoption of genome sequencing in research ... million variants per human genome, data analysis has become ...
Breaking Biology News(10 mins):Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 3Microbes evolve faster than ocean can disperse them 2Tute Genomics Launches MyGene Portal for Genome-guided Medicine 2Tute Genomics Launches MyGene Portal for Genome-guided Medicine 3
... Jan. 26, 2011 TGen Drug Development (TD2) ... should help speed new drugs safely into human testing ... Scottsdale, Ariz., provides drug development firms with expertise in ... regulatory approval steps of getting new drugs to patients ...
... ribbon worm discovered in Kosterhavet National Park in 2007 ... Pseudomicrura afzelii , a form of nemertean or ... at the University of Gothenburg, Sweden, using DNA technology. ... from the traditional, highly labour-intensive way of describing a ...
... 25, 2011Give caffeine to cells engineered to produce viruses used ... 8-times more virus, according to a paper published in ... Ann Liebert, Inc. ( www.liebertpub.com ). The paper is available ... inexpensive strategy for increasing lentivirus production was developed by Brian ...
Cached Biology News:Arizona companies team up, providing quick development of cancer drugs 2Researchers register new species using DNA-based description 2
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
NORMAL DONOR DONKEY SERUM...
Whole blood is collected from canines (any breed, either sex), refrigerated within 6 hours, processed within 24 hours and frozen at -20C....
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
Biology Products: